

Primary Hyperparathyroidism Committee meeting 5

Date: 18/01/2018

Location: NGC Boardroom

Minutes: Confirmed

Committee members present:		
Jonathan Mant (Chair) (JM)		(Present for notes 1 – 5)
Terry Aspray (TA)		(Present for notes 1 – 5)
Julie Cox (JC)		(Present for notes 1 – 5)
Parijat De (PD)		(Present for notes 1 – 5)
Joy Foster (JF)		(Present for notes 1 – 5)
Neil Gittoes (NG)		(Present for notes 1 – 5)
Fausto Palazzo (FP)		(Present for notes 1 – 5)
Peter Selby (PS)		(Present for notes 1 – 5)
Anthony Skene (AS)		(Present for notes 1 – 5)
Nicholas Thomson (NT)		(Present for notes 1 – 5)

In attendance:		
Katie Broomfield (KB)	Document Editor/Process Assistant	(Present for notes 1 – 5)
Sharangini Rajesh (SR)	Research Fellow	(Present for notes 1 – 5)
Sharon Swain (SS)	Associate Director/Guideline Lead	(Present for notes 1 – 5)
Emily Terrazas-Cruz (ETC)	Senior Research Fellow	(Present for notes 1 – 5)
David Wonderling (DW)	Head of Health Economics	(Present for notes 1 – 5)
Kyann Zhang (KZ)	Health Economist	(Present for notes 1 – 5)

Apologies:	
Emma Brockis (EB)	Senior Health Economist, NGC
Jill Cobb	Information Specialist, NGC
Meredith Faust (MF)	Project Manager, NGC
Imran Jawaid (IJ)	Guideline Committee

Judith McBride (JMB)	Senior Medical Editor, NICE
Nick Staples (NS)	Guideline Commissioning Manager, NICE

1. Welcome and objectives for the meeting

The Chair welcomed the Committee members and attendees to the fifth meeting on primary hyperparathyroidism.

The Chair informed the Committee that apologies had been received. These are noted above.

The Chair outlined the objectives of the meeting.

Introductions

2. Confirmation of matter under discussion, and declarations of interest

The Chair asked everyone to declare verbally any interests that have arisen since application. No new interests were received for this committee meeting.

The DOI register was made available to the Committee chair. The chair reviewed the DOI register and deemed that none of the original DOIs were in conflict with the agenda topics and clinical questions under discussion at the meeting.

The Chair asked AS and FP to explain to the committee what type of surgery they undertake in their private practices. They explained that their private practice is the same as their NHS practice (i.e. focussed surgery or 'open' surgery/four-gland exploration as indicated). The chair and guideline lead agreed that this was consistent with current NICE policy.

3. Minutes of the last meeting

The committee reviewed the minutes from the last meeting and agreed that they were a true and accurate account of the meeting.

The Chair confirmed that all matters arising had been completed or were in hand.

4. Presentations and discussion

4.1 SS led a discussion on the recommendations for diagnostic tests.

4.2 SR presented the clinical evidence for the surgical interventions review. KZ presented the unit costs for this review. The committee discussed the evidence.

4.3 KZ gave an update on health economic modelling.

4.4 ETC presented the clinical evidence for the bisphosphonates review. KZ

presented the economic evidence for this review. The committee discussed the evidence.

4.5 The committee discussed the proposed approach to the question on timing of re-operation.

5. Any other business

The group discussed next steps and agreed action points.

Date of next meeting: 28/02/2017

Location of next meeting: Sloane Room, Royal College of Physicians